Evidence map›Paper›PMID 33389470›Full record

ArticleNeurochemical research2021

Protective Effects of 28-O-Caffeoyl Betulin (B-CA) on the Cerebral Cortex of Ischemic Rats Revealed by a NMR-Based Metabolomics Analysis.

Xia Liu, Zhi Ruan, Xing-Cheng Shao, Hong-Xuan Feng, Lei Wu, Wei Wang, Hong-Min Wang, Hong-Yan Mu, Ru-Jun Zhang, Wei-Min Zhao and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Xia Liu *Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Zhi Ruan *CAS Key Laboratory of Receptor Research, Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xing-Cheng Shao *Department of Natural Product Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Hong-Xuan FengCAS Key Laboratory of Receptor Research, Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Lei WuCAS Key Laboratory of Receptor Research, Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Wei WangCAS Key Laboratory of Receptor Research, Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Hong-Min WangDepartment of Natural Product Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Hong-Yan MuDepartment of Natural Product Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Ru-Jun ZhangDepartment of Natural Product Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Wei-Min ZhaoDepartment of Natural Product Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. wmzhao@simm.ac.cn.
Hai-Yan ZhangCAS Key Laboratory of Receptor Research, Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. hzhang@simm.ac.cn.
Nai-Xia ZhangDepartment of Analytical Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. nxzhang@simm.ac.cn.ORCID http://orcid.org/0000-0003-1289-6441
Chinese Academy of Sciences · CN

Funding

Key New Drug Creation and Manufacturing Program" of China 2018ZX09711002Key New Drug Creation and Manufacturing Program" of China 2018ZX09711002-002-014National Natural Science Foundation of China 21778061National Natural Science Foundation of China 21877119
6 · The paper itself

Abstract

28-O-caffeoyl betulin (B-CA) has been demonstrated to reduce the cerebral infarct volume caused by transient middle cerebral artery occlusion (MCAO) injury. B-CA is a novel derivative of naturally occurring caffeoyl triterpene with little information associated with its pharmacological target(s). To date no data is available regarding the effect of B-CA on brain metabolism. In the present study, a

Indexed as

AnimalsBetulinic AcidCaffeic AcidsCerebral CortexInfarction, Middle Cerebral ArteryMaleMetabolic DiseasesMetabolomeMetabolomicsNeuroprotective AgentsProton Magnetic Resonance SpectroscopyRatsRats, Sprague-DawleyROC CurveTriterpenes28-O-caffeoyl betulinBetulinic AcidCaffeic AcidsNeuroprotective AgentsTriterpenes28-O-caffeoyl betulinCerebral ischemia–reperfusionMetabolomicsNeuroprotectionNMR

Identifiers

PMID33389470
OpenAlexW3197742331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.